Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

High concentration antibody-containing liquid formulation

a liquid formulation, high concentration technology, applied in the direction of antibody medical ingredients, immunological disorders, drug compositions, etc., can solve the problems of antibody molecules being lost, bioactivity is lost, and there is not yet a technology sufficient to prevent dimerization and deamidation

Inactive Publication Date: 2014-01-02
F HOFFMANN LA ROCHE INC
View PDF4 Cites 22 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes a method to prevent antibodies in liquid form from clumping together. This is done by adding two specific ingredients, methionine and and, to the liquid formulation. The technical effect of this is that it helps to keep the antibodies in a more stable state, which makes them easier to handle and work with in various applications.

Problems solved by technology

Further, in cases where a protein is stored in a form of a solution having a high concentration, problematic degradation occurs, which includes a generation of insoluble and / or soluble aggregates; and it is necessary to prevent such degradation.
In cases where a liquid formulation is stored for a long time, a problem exists in that a bioactivity of antibody molecules is lost due to deamidation of amino acid residues such as aspargine residues.
However, for liquid formulations containing a high concentration of an antibody, there does not yet exist a technology that is sufficient to prevent dimerization and deamidation.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • High concentration antibody-containing liquid formulation
  • High concentration antibody-containing liquid formulation
  • High concentration antibody-containing liquid formulation

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0094]Stabilizing Effects by Combination of Arginine and Methionine

[0095]Liquid formulations containing anti-IL-6 receptor humanized antibody were evaluated for an influence on stabilization of the formulations obtained by use of a combination of arginine and methionine.

[0096]In this study, to evaluate the effects by the combination of arginine and methionine, evaluation samples numbered A1 to A9 were prepared. Prescriptions for the evaluation samples were as follows:

TABLE 1-1[Prescriptions]SampleAntibodyArgMetPolysorbate 80Histidine bufferNo.mg / mLmMmMmg / mLmMpHA1180——0.5206.0A2180 50—0.5206.0A3180100—0.5206.0A4180150—0.5206.0A5180200—0.5206.0A6180300—0.5206.0A7180100100.5206.0A8180100300.5206.0A9180100500.5206.0

[0097]To evaluate stability of the liquid formulations, each sample was subjected to a heat acceleration test (stored at 40° C. for 3 months and at 25° C. for 6 months, respectively). The purity of the antibody before and after the heat acceleration test was evaluated by gel ...

example 2

[0106]Inhibitory Effect by Arginine against Deamidation

[0107]Liquid formulations containing and-IL-6 receptor humanized antibody were evaluated for influence on the deamidation by arginine.

[0108]In this study, evaluation samples numbered A10 to A15 and numbered A16 to A18, containing different amounts of arginine and methionine, respectively, were prepared.

[0109]Prescriptions for the evaluation samples were as follows:

TABLE 2-1[Prescriptions]SampleAntibodyArgMetPolysorbate 80Histidine bufferNo.mg / mLmMmMmg / mLmMpHA10180——0.5206.0A11180 50—0.5206.0A12180100—0.5206.0A13180150—0.5206.0A14180200—0.5206.0A15180300—0.5206.0A16180—100.5206.0A17180—300.5206.0A18180—500.5206.0

[0110]To evaluate the stability of the liquid formulations, each sample was subjected to a heat acceleration test (stored at 40° C. for 3 months and at 25° C. for 6 months, respectively). The purities of the antibody before and after the heat acceleration test were evaluated by ion-exchange chromatography (IEC). The analy...

example 3

[0119]Stabilizing Effects by Combination of Arginine and Methionine (2)

[0120]As in Example 1, liquid formulations containing receptor humanized antibody were evaluated for influence on stabilization of the formulations obtained by use of a combination of arginine and methionine.

[0121]In this study, to evaluate effects of the combination of arginine and evaluation samples numbered A19 to A27 were prepared. Prescriptions for the evaluation samples were as follows:

TABLE 3-1[Prescriptions]SampleAntibodyArgMetPolysorbate 80Histidine bufferNo.mg / mLmMmMmg / mLmMpHA19180——0.5206.0A20180 50—0.5206.0A21180100—0.5206.0A22180150—0.5206.0A23180200—0.5206.0A24180300—0.5206.0A25180100100.5206.0A26180100300.5206.0A27180100500.5206.0

[0122]To evaluate the stability of the liquid formulations, each sample was subjected to a light acceleration test (total illuminance 1,200,000 lux and total near-ultraviolet radiation energy: 200 W·h / m2). The purities of the antibody before and after the light acceleratio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage.The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine.

Description

TECHNICAL FIELD[0001]The present invention relates to an antibody-containing formulation, and particularly, to a stable liquid formulation containing a high concentration of an antibody.BACKGROUND ART[0002]In recent years, various antibody formulations have been developed and used in practice. Many such antibody formulations are used in intravenous injection. However, due to needs of a clinical site, there is an increasing demand for development of an antibody-containing formulation that can be administered as a self-injectable subcutaneous injection.[0003]In designing an antibody-containing formulation for subcutaneous injection, since a dose of an antibody per administration is large (about 100 mg to 200 mg) and an amount of an injection solution is generally limited in subcutaneous injection, it is necessary to increase a concentration of an antibody in a liquid to be administered. In view of this, in many cases, high concentration formulations are used, which are prepared by the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K1/14
CPCC07K1/14A61K9/0019A61K39/3955A61K39/39591A61K47/183A61K47/26C07K2317/76C07K16/2866C07K2317/24A61K47/20A61P37/02A61P43/00A61K39/00A61K39/395A61K2039/505
Inventor MORICHIKA, TOSHIYUKIKAMEOKA, DAISUKEIMAEDA, YOSHIMIMAEDA, TERUTOSHISTAUCH, OLIVER BORIS
Owner F HOFFMANN LA ROCHE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com